Cannabis Sativa, Inc. (CBDS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cannabis Sativa, Inc. (CBDS) trades at $0.03. Cannabis Sativa, Inc. operates in the burgeoning cannabis industry, providing telemedicine services for medical marijuana referrals. Market cap: $4.27M, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for CBDS: CBDS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CBDS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CBDS: 1/1 perspectives are bearish.
Cannabis Sativa, Inc. (CBDS) Healthcare & Pipeline Overview
Cannabis Sativa, Inc. focuses on telemedicine services for medical marijuana recommendations through its PrestoDoctor platform, alongside developing cannabis-infused products and branded merchandise. Operating within the evolving cannabis industry, the company seeks to capitalize on the increasing acceptance of medical marijuana, while navigating a complex regulatory landscape.
What Is the Investment Thesis for CBDS?
Cannabis Sativa, Inc. presents a high-risk, high-reward investment opportunity within the evolving cannabis industry. The company's focus on telemedicine through PrestoDoctor offers a scalable model for medical marijuana recommendations, capitalizing on increasing legalization trends. However, the company's small size, limited financials (negative profit margin of -195.0%), and OTC listing introduce significant risks. Growth hinges on successful product development, market expansion, and navigating the complex regulatory landscape. Investors should carefully consider the company's financial stability, competitive positioning, and the inherent uncertainties of the cannabis market before investing.
Based on FMP financials and quantitative analysis
CBDS Key Highlights
- Gross Margin of 63.4% indicates potential for profitability if sales volume increases.
- Operating in the growing cannabis industry, capitalizing on increasing acceptance of medical marijuana.
- PrestoDoctor telemedicine platform offers a scalable model for medical marijuana recommendations.
- Development of cannabis-infused products diversifies revenue streams beyond telemedicine.
- Market capitalization of $0.00B reflects the company's small size and early stage of development.
Who Are CBDS's Competitors?
Who Are CBDS's Competitors?
CBDS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACRDF Acreage Holdings, Inc. | $0.12 | +0.00% | $4.88M | 41 |
| GHSI Guardion Health Sciences, Inc. | $3.25 | +0.00% | $4.17M | 46 |
| IPCIF Intellipharmaceutics International Inc. | $0.15 | +0.00% | $4.96M | 54 |
| HNGE Hinge Health, Inc. | $54.50 | +1.15% | 5B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.00 | +0.00% | $20.00M | 67 |
| CRBKF Carebook Technologies Inc. | $0.03 | +0.00% | $6.84M | 64 |
| FOXO FOXO Technologies Inc. | $0.00 | +0.00% | 3K | 63 |
| NH NantHealth, Inc. | $1.35 | +0.00% | 52 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CBDS's Key Strengths?
- Telemedicine platform offers scalability.
- Development of cannabis-infused products diversifies revenue streams.
- Established Wild Earth Naturals brand.
- Intellectual property license for medical marijuana edibles.
What Are CBDS's Weaknesses?
- Small size and limited resources.
- Negative profit margin.
- OTC listing increases risk.
- Reliance on evolving cannabis regulations.
What Could Drive CBDS Stock Higher?
- Potential legalization of medical marijuana in new states could expand the market for PrestoDoctor.
- Development and launch of new cannabis-infused products could drive revenue growth.
- Strategic partnerships with cannabis dispensaries could enhance brand visibility and market reach.
What Are the Key Risks for CBDS?
- Evolving cannabis regulations could negatively impact the company's operations.
- Intense competition could erode market share and profitability.
- Small size and limited resources could hinder growth and expansion.
- OTC listing increases risk of fraud and manipulation.
- Negative profit margin raises concerns about financial sustainability.
What Are the Growth Opportunities for CBDS?
- Expansion of PrestoDoctor into new states: As more states legalize medical marijuana, Cannabis Sativa, Inc. can expand its telemedicine platform to serve a wider patient base. The medical cannabis market is projected to reach $25 billion by 2025, presenting a substantial opportunity for growth. Successful expansion requires navigating varying state regulations and establishing partnerships with local physicians.
- Development and launch of new cannabis-infused products: The company's pipeline of products, including lozenges, balms, and creams, offers a potential avenue for revenue diversification. The market for cannabis-infused products is projected to reach $17 billion by 2027. Successful product launches require effective marketing, quality control, and compliance with labeling regulations.
- Strategic partnerships with cannabis dispensaries: Collaborating with dispensaries can provide Cannabis Sativa, Inc. with access to a broader customer base and enhance brand visibility. Partnerships can involve cross-promotion, product placement, and joint marketing initiatives. The dispensary market is highly fragmented, requiring careful selection of partners.
- Expansion of branded merchandise offerings: The company's Wild Earth Naturals brand can be expanded to include a wider range of apparel, accessories, and lifestyle products. Branded merchandise can generate incremental revenue and enhance brand awareness. Successful expansion requires effective design, sourcing, and marketing.
- Intellectual property licensing: Cannabis Sativa, Inc.'s intellectual property license for medical marijuana edibles presents an opportunity for generating licensing revenue. The company can license its technology to other companies in the cannabis industry, generating a recurring revenue stream. Successful licensing requires effective negotiation and enforcement of licensing agreements.
What Opportunities Does CBDS Have?
- Expansion into new states.
- Strategic partnerships with dispensaries.
- Expansion of branded merchandise offerings.
- Licensing of intellectual property.
What Threats Does CBDS Face?
- Intense competition.
- Evolving cannabis regulations.
- Potential for federal prohibition.
- Fluctuations in cannabis prices.
What Are CBDS's Competitive Advantages?
- First-mover advantage in telemedicine for medical marijuana recommendations.
- Proprietary PrestoDoctor platform.
- Intellectual property license for medical marijuana edibles.
- Established Wild Earth Naturals brand.
What Does CBDS Do?
Cannabis Sativa, Inc., formerly known as Ultra Sun Corporation, rebranded in November 2013 to focus on the cannabis and cannabidiol (CBD) industries. The company's primary business is providing telemedicine online referral services for individuals seeking medical marijuana cards in the United States. Its core platform, PrestoDoctor, facilitates virtual consultations with physicians via video conferencing, enabling patients to obtain medical marijuana recommendations. Beyond telemedicine, Cannabis Sativa, Inc. is actively developing a range of cannabis-infused products, including lozenges for throat irritation, Recover balm for pain relief, Trauma Cream, and a line of skincare products under the Face Garden, Body Garden, and Lip Garden brands. The company also markets branded apparel and merchandise through its Wild Earth Naturals website. Additionally, Cannabis Sativa, Inc. holds an intellectual property license for the manufacture of medical marijuana edibles. Headquartered in Mesquite, Nevada, the company serves both the cannabidiol and marijuana markets, aiming to establish a diversified presence in the cannabis industry.
What Products and Services Does CBDS Offer?
- Provides telemedicine services for medical marijuana recommendations.
- Operates the PrestoDoctor online platform.
- Connects patients with physicians for virtual consultations.
- Develops cannabis-infused products, including lozenges, balms, and creams.
- Markets branded apparel and merchandise through Wild Earth Naturals.
- Holds an intellectual property license for medical marijuana edibles.
How Does CBDS Make Money?
- Generates revenue from telemedicine consultations through PrestoDoctor.
- Sells cannabis-infused products through online and retail channels.
- Markets branded apparel and merchandise through Wild Earth Naturals.
- Potentially generates revenue through intellectual property licensing.
What Industry Does CBDS Operate In?
Cannabis Sativa, Inc. operates within the rapidly expanding cannabis industry, which is experiencing significant growth due to increasing legalization and acceptance of both medical and recreational marijuana. The market is characterized by intense competition, evolving regulations, and varying consumer preferences. Companies like Cannabis Sativa, Inc. are vying for market share in various segments, including telemedicine, infused products, and branded merchandise. Competitors include ACRDF (Acreage Holdings, Inc.), BRRGF (Curaleaf Holdings, Inc.), GHSI (Guardion Health Sciences, Inc.), HDRPF (Hydrofarm Holdings Group, Inc.), and IPCIF (iPower Inc.).
Who Are CBDS's Key Customers?
- Individuals seeking medical marijuana cards.
- Patients requiring medical cannabis for various conditions.
- Consumers interested in cannabis-infused products.
- Customers of Wild Earth Naturals branded apparel and merchandise.
CBDS Financials
CBDS Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Wednesday
· Dec 11, 2019
-
Stocks That Hit 52-Week Lows On Monday
· Nov 4, 2019
-
Stocks That Hit 52-Week Lows On Wednesday
· Oct 2, 2019
CBDS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CBDS.
Price Targets
Wall Street price target analysis for CBDS.
CBDS MoonshotScore
What does this score mean?
The MoonshotScore rates CBDS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Who Are CBDS's Competitors?
Leadership: David M. Tobias
Managing Director
David M. Tobias serves as the Managing Director of Cannabis Sativa, Inc. His background includes experience in managing small teams and overseeing the company's operations. Information regarding his prior roles and educational background is not available. He is responsible for guiding the company's strategic direction and overseeing its day-to-day activities.
Track Record: Under David M. Tobias's leadership, Cannabis Sativa, Inc. has focused on developing its PrestoDoctor telemedicine platform and expanding its product offerings. The company has also navigated the evolving regulatory landscape of the cannabis industry. Specific milestones and achievements under his leadership are not available.
CBDS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cannabis Sativa, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial information available and are subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume and wide bid-ask spread increase volatility.
- Higher risk of fraud and manipulation compared to listed exchanges.
- Limited regulatory oversight increases risk of non-compliance.
- Potential for delisting and loss of investment.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's competitive positioning and market share.
- Evaluate the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Confirm the legitimacy of the company's operations and assets.
- Operation of the PrestoDoctor telemedicine platform.
- Development of cannabis-infused products.
- Marketing of branded apparel and merchandise.
- Intellectual property license for medical marijuana edibles.
Common Questions About CBDS (Healthcare)
What does Cannabis Sativa, Inc. do?
Cannabis Sativa, Inc. primarily operates in the medical cannabis sector through its PrestoDoctor platform, providing telemedicine services for patients seeking medical marijuana recommendations. The company connects patients with licensed physicians via video conferencing, facilitating the process of obtaining medical marijuana cards. Additionally, Cannabis Sativa, Inc. develops and markets cannabis-infused products and branded merchandise, aiming to diversify its revenue streams and establish a presence in various segments of the cannabis industry.
What do analysts say about CBDS stock?
As of March 16, 2026, there is no readily available analyst coverage or consensus on Cannabis Sativa, Inc. (CBDS) due to its OTC listing and small market capitalization. Key valuation metrics such as price-to-earnings ratio (-1.69) and profit margin (-195.0%) reflect the company's current financial challenges. Investors should conduct their own thorough due diligence and consider the inherent risks associated with investing in small-cap OTC stocks before making any investment decisions.
What are the main risks for CBDS?
Cannabis Sativa, Inc. faces several key risks, including evolving cannabis regulations, intense competition, limited financial resources, and the inherent risks associated with its OTC listing. Changes in state or federal cannabis laws could significantly impact the company's operations and market opportunities. The company's small size and negative profit margin raise concerns about its financial sustainability. The OTC listing increases the risk of fraud, manipulation, and limited liquidity, requiring careful due diligence from investors.
What are the key factors to evaluate for CBDS?
Evaluating CBDS involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Telemedicine platform offers scalability. Primary risk to monitor: Evolving cannabis regulations could negatively impact the company's operations. This is not financial advice.
How frequently does CBDS data refresh on this page?
CBDS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CBDS's recent stock price performance?
Recent price movement in Cannabis Sativa, Inc. (CBDS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Telemedicine platform offers scalability. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CBDS overvalued or undervalued right now?
Determining whether Cannabis Sativa, Inc. (CBDS) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CBDS?
Before investing in Cannabis Sativa, Inc. (CBDS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- Analyst coverage is non-existent due to the company's size and OTC listing.
- The cannabis industry is subject to rapid regulatory changes, which could impact the company's prospects.